The estimated Net Worth of David Alexandre C Gros is at least $14.6 mil dollars as of 22 February 2016. David Gros owns over 1,000 units of Novus Therapeutics Inc stock worth over $14,600 and over the last 9 years he sold NVUS stock worth over $0. In addition, he makes $0 as Chief Executive Officer e Director at Novus Therapeutics Inc.
David has made over 2 trades of the Novus Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of NVUS stock worth $62,750 on 22 February 2016.
The largest trade he's ever made was buying 1,000 units of Novus Therapeutics Inc stock on 22 February 2016 worth over $62,750. On average, David trades about 222 units every 0 days since 2015. As of 22 February 2016 he still owns at least 1,000 units of Novus Therapeutics Inc stock.
You can see the complete history of David Gros stock trades at the bottom of the page.
Dr. David-Alexandre C. Gros M.D. serves as Chief Executive Officer, Director of the Company. He had been serving as an advisor to Novus since May 2020 and joined Novus from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where since May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Since November 2018, he has also served on the board of directors of Eliem Pharmaceuticals. He previously served as President and Chief Operating Officer of Neurocrine Biosciences, Inc., from January to December 2017. Beforehand, he was the Senior Vice President, Chief Business Officer and Principal Financial Officer, and was a member of the Management Board of Alnylam Pharmaceuticals, Inc., from June 2015 to January 2017. Prior to joining Alnylam, Dr. Gros served as Executive Vice President and Chief Strategy Officer at Sanofi SA, from September 2011 to June 2015, where he was a member of the Executive Committee. Prior to Sanofi, he held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners from 2009 to 2011 and Merrill Lynch from 2006 to 2009, and in management consulting at McKinsey & Company from 2002 to 2006. Dr. Gros holds an M.D. from The Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School and a B.A. from Dartmouth College.
David Gros is 48, he's been the Chief Executive Officer e Director of Novus Therapeutics Inc since 2020. There are 4 older and no younger executives at Novus Therapeutics Inc. The oldest executive at Novus Therapeutics Inc is Gary Lyons, 68, who is the Independent Director.
David's mailing address filed with the SEC is C/O NOVUS THERAPEUTICS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE, CA, 92612.
Over the last 7 years, insiders at Novus Therapeutics Inc have traded over $2,287,089 worth of Novus Therapeutics Inc stock and bought 1,499,013 units worth $7,312,148 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Israel Gp Ltd.Orbi Med Isra..., eErez Chimovits. On average, Novus Therapeutics Inc executives and independent directors trade stock every 100 days with the average trade being worth of $1,832,709. The most recent stock trade was executed by Israel Gp Ltd.Orbi Med Isra... on 2 December 2020, trading 103,200 units of NVUS stock currently worth $2,229,120.
Novus Therapeutics Inc executives and other stock owners filed with the SEC include: